Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Preferred Stock Liabilities (2024 - 2026)

Translational Development Acquisition's Preferred Stock Liabilities history spans 3 years, with the latest figure at $183.3 million for Q1 2026.

  • On a quarterly basis, Preferred Stock Liabilities rose 4.02% to $183.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $183.3 million, a 4.02% increase, with the full-year FY2025 number at $181.7 million, up 4.19% from a year prior.
  • Preferred Stock Liabilities came in at $183.3 million for Q1 2026, up from $181.7 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $183.3 million in Q1 2026, with the low at $174.4 million in Q4 2024.
  • Historically, Preferred Stock Liabilities has averaged $178.9 million across 3 years, with a median of $179.0 million in 2025.
  • Biggest five-year swings in Preferred Stock Liabilities: increased 4.19% in 2025 and later rose 4.02% in 2026.
  • Year by year, Preferred Stock Liabilities stood at $174.4 million in 2024, then increased by 4.19% to $181.7 million in 2025, then increased by 0.89% to $183.3 million in 2026.
  • Business Quant data shows Preferred Stock Liabilities for TDAC at $183.3 million in Q1 2026, $181.7 million in Q4 2025, and $179.9 million in Q3 2025.